drug

5% Dextrose solution

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Beth Israel Deaconess Medical Center
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Sodium Nitroprusside in Early Course Schizophrenia
NCT04986072Phase 2Terminated

KOLs & investigators

1
Paulo Lizano, MD, PhDKOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Beth Israel Deaconess Medical Center
company
trial
Sodium Nitroprusside in Early Course Schizophrenia
PHASE2
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
Schizoaffective Disorder
indication
KOL
Paulo Lizano, MD, PhD
KOL score 5
person